1
|
Weitzman ER, Alegria M, Caplan A, Dowling D, Evans J, Fisher CE, Jordan A, Kossowsky J, Landau M, Larson H, Levy O, Levy S, Mnookin S, Reif S, Ross J, Sherman AC. Social complexity of a fentanyl vaccine to prevent opioid overdose conference proceedings: Radcliffe Institute for Advanced Study conference proceedings. Vaccine 2025; 44:126324. [PMID: 39317618 DOI: 10.1016/j.vaccine.2024.126324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2024] [Accepted: 09/04/2024] [Indexed: 09/26/2024]
Abstract
Despite significant public health attention and investment, hundreds of thousands of individuals have suffered fatal opioid overdose since the onset of the opioid crisis. Risk of opioid overdose has been exacerbated by the influx of fentanyl, a powerful synthetic opioid, into the drug supply. The National Institutes of Health Helping End Addiction Long-term (HEAL) Initiative is supporting the development of vaccines targeting fentanyl to protect against overdose. If successful, a vaccine would induce anti-fentanyl antibodies to sequester fentanyl (but not other opioids) in the blood, preventing fentanyl from crossing into the brain and reaching the central nervous system where it can cause overdose. Introduction of an overdose preventing strategy that relies on a vaccine to confer passive protection may be impactful. However, vaccines are poorly understood by the public and politicized. Moreover, the overdose ecosystem is complex and extends across numerous social, economic, medical, and cultural systems. As such, optimal use of a vaccine strategy to address overdose may benefit from multidisciplinary consideration of the social, ethical, and systemic factors that influence substance use and overdose that may also impact the acceptability of a fentanyl vaccine and related implementation strategies. In March 2022, Dr. Elissa Weitzman convened a two-day conference at the Harvard Radcliffe Institute for Advanced Study on the Social Complexity of a Fentanyl Vaccine to Prevent Opioid Overdose. In all, 19 professionals from diverse disciplines (medicine, psychology, history, ethics, immunology, vaccinology, communications, policy) attended the conference and led discussions that centered on population health and epidemiology, history of medicine and frameworks for understanding substance use, ethics, decision-making and attitudes, and operational issues to the question of a novel immunotherapy targeting fentanyl overdose. Participants also debated the risks and benefits of vaccine administration in response to fictional clinical case vignettes. A summary of the conference presentations and discussions follows.
Collapse
Affiliation(s)
- Elissa R Weitzman
- Division of Addiction Medicine, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, United States; Division of Adolescent and Young Adult Medicine, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, United States; Computational Health Informatics Program, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, United States; Department of Pediatrics, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, United States.
| | - Margarita Alegria
- Department of Medicine, Massachusetts General Hospital, 50 Staniford St, Boston, MA 02114, United States; Department of Medicine, Harvard Medical School, 25 Shattuck St, Boston, MA, United States; Department of Psychiatry, Harvard Medical School, 25 Shattuck St, Boston, MA, United States
| | - Arthur Caplan
- New York University Grossman School of Medicine, 550 1(st) Ave, New York, NY 10016, United States
| | - David Dowling
- Precision Vaccines Program, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, United States; Department of Pediatrics, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, United States
| | - Jay Evans
- Inimmune Corporation, 1121 E Broadway St, Missoula, MT 59802, United States
| | - Carl Erik Fisher
- Department of Psychiatry, Columbia University, 1051 Riverside Drive, New York, New York 10032, United States
| | - Ayana Jordan
- New York University Grossman School of Medicine, 550 1(st) Ave, New York, NY 10016, United States
| | - Joe Kossowsky
- Department of Anesthesiology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, United States; Department of Anesthesia, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, United States
| | | | - Heidi Larson
- Department of Infectious Disease Epidemiology and Dynamics, London School of Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT, UK
| | - Ofer Levy
- Precision Vaccines Program, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, United States; The Broad Institute, 415 Main St, Cambridge, MA 02142, United States; Department of Pediatrics, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, United States
| | - Sharon Levy
- Division of Addiction Medicine, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, United States; Department of Pediatrics, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, United States
| | - Seth Mnookin
- School of Humanities, Arts, and Social Sciences, Massachusetts Institute of Technology, 160 Memorial Dr, Cambridge, MA 02139, United States
| | - Sharon Reif
- Heller School for Social Policy and Management, Brandeis University, 415 South St, Waltham, MA 02453, United States
| | - Jennifer Ross
- Division of Addiction Medicine, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, United States; Department of Pediatrics, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, United States
| | - Amy Caryn Sherman
- Precision Vaccines Program, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, United States; Division of Infectious Disease, Brigham and Women's Hospital, 15 Francis St., Boston, MA 02115, United States; Department of Pediatrics, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, United States
| |
Collapse
|
2
|
Xu Y, Gao G, Sun X, Liu Q, Li C. ATPase Inhibitory Factor 1 Is Critical for Regulating Sevoflurane-Induced Microglial Inflammatory Responses and Caspase-3 Activation. Front Cell Neurosci 2021; 15:770666. [PMID: 34975409 PMCID: PMC8714895 DOI: 10.3389/fncel.2021.770666] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2021] [Accepted: 11/02/2021] [Indexed: 02/05/2023] Open
Abstract
Postoperative delirium (POD) is one of the most important complications after surgery with general anesthesia, for which the neurotoxicity of general anesthetics is a high-risk factor. However, the mechanism remains largely unknown, which also hinders the effective treatment of POD. Here, we confirmed that a clinical concentration of the general anesthetic sevoflurane increased the expression of inflammatory factors and activated the caspase-3 by upregulating ATPase inhibitory factor 1 (ATPIF1) expression in microglia. Upregulation of ATPIF1 decreased the synthesis of ATP which is an important signaling molecule secreted by microglia. Extracellular supplementation with ATP attenuated the microglial inflammatory response and caspase-3 activation caused by sevoflurane or overexpression of ATPIF1. Additionally, the microglial inflammatory response further upregulated ATPIF1 expression, resulting in a positive feedback loop. Animal experiments further indicated that intraperitoneal injection of ATP significantly alleviated sevoflurane anesthesia-induced POD-related anxiety behavior and memory damage in mice. This study reveals that ATPIF1, an important protein regulating ATP synthesis, mediates sevoflurane-induced neurotoxicity in microglia. ATP supplementation may be a potential clinical treatment to alleviate sevoflurane-induced POD.
Collapse
Affiliation(s)
- Yaru Xu
- Department of Anesthesiology and Perioperative Medicine, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
- Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
- Clinical Research Center for Anesthesiology and Perioperative Medicine, Tongji University, Shanghai, China
- Department of Anesthesiology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
| | - Ge Gao
- Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
| | - Xiaoru Sun
- Department of Anesthesiology and Perioperative Medicine, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
- Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
- Clinical Research Center for Anesthesiology and Perioperative Medicine, Tongji University, Shanghai, China
| | - Qidong Liu
- Anesthesia and Brain Research Institute, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
- Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Orthopedic Department of Tongji Hospital, School of Medicine, Tongji University, Shanghai, China
| | - Cheng Li
- Department of Anesthesiology and Perioperative Medicine, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
- Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
- Clinical Research Center for Anesthesiology and Perioperative Medicine, Tongji University, Shanghai, China
| |
Collapse
|
3
|
Sejdiu A, Pereira KN, Joundi H, Patel YR, Basith SA, Ayala V, Mathialagan K, Majumder P. Demographic Pattern and Mortality Risk Factors for Prescription Opioid Overdose Hospitalizations: Results From Nationwide Inpatient Sample Analysis. Cureus 2021; 13:e15674. [PMID: 34277265 PMCID: PMC8281797 DOI: 10.7759/cureus.15674] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/15/2021] [Indexed: 11/05/2022] Open
Abstract
Objectives To explore the demographic patterns of hospitalizations related to prescription opioid overdose (POD) and evaluate the mortality risk of association in POD inpatients. Methodology We conducted a cross-sectional study using the Nationwide Inpatient Sample of 184,711 POD inpatients. A binomial logistic regression model was used to evaluate the odds ratio (OR) of association for mortality risk due to comorbidities (substance use disorders (SUD) and medical complications) in POD inpatients. Results POD inpatients were majorly females (54.1%), older adults aged 51-75 years (48.5%), whites (81.5%), and from lower household income quartet (32.8%). The most prevalent comorbid SUD among POD inpatients was alcohol (15.7%), followed by cannabis (5.7%), cocaine (4.2%), and amphetamine (1.8%). Comorbid alcohol use disorders had a minimally increased association with mortality but were not statistically significant (OR = 1.036; P = 0.438). POD in patients with cardiac arrest had the highest risk of mortality (OR = 103.423; P < 0.001), followed by shock (OR = 15.367; P < 0.001), coma (OR = 13.427; P < 0.001), and respiratory failure (OR = 12.051; P < 0.001). Conclusions Our study indicates that the hospitalizations related to POD were more prevalent among females, elders between 51 and 75 years of age, whites, and those in the lower household income quartet. The prevalence of prescription opioid use and the hospitalization related to POD remains a significant public health issue. POD inpatients with medical complications were at a higher risk of mortality than with comorbid SUD.
Collapse
Affiliation(s)
- Albulena Sejdiu
- Psychiatry, Saints Cyril and Methodius University, Skopje, MKD
| | | | - Hajara Joundi
- Internal Medicine, University Cadi Ayyad, Faculty of Medicine and Pharmacy, Marrakesh, MAR
| | | | - Sayeda A Basith
- Psychiatry and Behavioral Sciences, Medical University of the Americas, Charlestown, KNA
| | - Victoria Ayala
- Psychiatry, Ross University School of Medicine, Bridgetown, BRB
| | | | - Pradipta Majumder
- Psychiatry, Drexel University College of Medicine, Philadelphia, USA.,Psychiatry, WellSpan Health, York, USA
| |
Collapse
|